Treatment patterns for AL amyloidosis after frontline daratumumab, bortezomib, cyclophosphamide, and dexamethasone treatment failures

Leukemia. 2024 Apr 9. doi: 10.1038/s41375-024-02243-5. Online ahead of print.

Authors

Saurabh Zanwar¹, Morie A Gertz¹, Eli Muchtar¹, Francis K Buadi¹, Taxiarchis Kourelis¹, Wilson Gonsalves¹, Ronald S Go¹, Suzanne Hayman¹, Prashant Kapoor¹, Moritz Binder¹, Joselle Cook¹, David Dingli¹, Nelson Leung¹, Yi Lin¹, Rahma Warsame¹, Amie Fonder¹, Miriam Hobbs¹, Yi Lisa Hwa¹, Robert A Kyle¹, S Vincent Rajkumar¹, Shaji Kumar¹, Angela Dispenzieri²

Affiliations

¹ Division of Hematology, Mayo Clinic, Rochester, MN, US.
² Division of Hematology, Mayo Clinic, Rochester, MN, US. dispenzieri.angela@mayo.edu.

PMID: 38594348
DOI: 10.1038/s41375-024-02243-5

No abstract available